Table 2. Risk of adverse events according to the presence of established CAD and the use of statin over 10 years.
| Adverse events | CAD (+) (n = 176) | CAD (−) (n = 611) | P value | Adjusted HRa (95% CI) | P value | Statin (+) (n = 407) | Statin (−) (n = 380) | P value | Adjusted HRa (95% CI) | P value |
|---|---|---|---|---|---|---|---|---|---|---|
| CV death | 31 (17.6) | 59 (9.6) | 0.002 | 1.62 (1.04–2.53) | 0.033 | 45 (11.1) | 45 (11.8) | 0.500 | 0.64 (0.41–0.98) | 0.041 |
| AVR | 13 (7.3) | 23 (3.7) | 0.030 | 1.63 (0.51–3.51) | 0.214 | 29 (7.1) | 7 (1.8) | < 0.001 | 1.86 (0.76–4.58) | 0.177 |
| Composite | 41 (23.2) | 82 (13.4) | < 0.001 | 1.32 (0.87–2.02) | 0.181 | 71 (17.4) | 52 (13.6) | 0.100 | 0.78 (0.53–1.15) | 0.209 |
Data are shown as number (%), unless otherwise specified. Adverse events expressed in number (%) are crude events over 10 years.
CAD = coronary artery disease, HR = hazard ratio, CI = confidence interval, CV = cardiovascular, AVR = aortic valve replacement.
aHR with 95% CI was adjusted with age, sex, hypertension, diabetes mellitus, chronic kidney disease, CAD, aortic stenosis etiology, and peak aortic valve velocity, aspirin, beta-blockers, and renin-angiotensin system inhibitors.